evid antiplatelet aggreg action doxazosin patient hypertens ex vivo studi eighteen patient mean age year studi patient diagnosi mild moder essenti hypertens diastol blood pressur mm Hg studi design singl blind phase phase placebo week phase II activ treatment week dose doxazosin week mg/day result doxazosin antihypertens effect dose depend systol diastol blood pressur effect heart rate doxazosin platelet aggreg epinephrin adenosin diphosph collagen dose-depend manner addit treatment doxazosin total serum cholesterol triglycerid level standard biochem paramet doxazosin distinct therapeut advantag modul atherogen thromboembol factor coronari heart diseas 